Switch theme
Sign up to access all valuation multiples
AS Latvijas Juras medicinas centrs is engaged in the provision of healthcare services. It operates hospitals and diagnostic centers. The company offers diagnostics services, magnetic resonance imaging, radiological diagnostics services, and ambulance services. It is also engaged in General medical practice activities, Special medical practice activities, Residential nursing care activities, Retail sale of medical and orthopedic goods in specialized stores, and Other personal service activities.
1996
359
Last FY Revenue $11.4M
Last FY EBITDA $0.8M
$4.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Latvijas Juras medicinas achieved revenue of $11.4M and an EBITDA of $0.8M.
Latvijas Juras medicinas expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Latvijas Juras medicinas valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $11.4M | XXX | XXX | XXX |
| Gross Profit | XXX | $0.3M | XXX | XXX | XXX |
| Gross Margin | XXX | 3% | XXX | XXX | XXX |
| EBITDA | XXX | $0.8M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 7% | XXX | XXX | XXX |
| EBIT | XXX | $0.1M | XXX | XXX | XXX |
| EBIT Margin | XXX | 1% | XXX | XXX | XXX |
| Net Profit | XXX | $0.2M | XXX | XXX | XXX |
| Net Margin | XXX | 2% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Latvijas Juras medicinas's stock price is EUR 6 (or $7).
Latvijas Juras medicinas has current market cap of EUR 5.0M (or $5.6M), and EV of EUR 4.1M (or $4.6M).
See Latvijas Juras medicinas trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.6M | $5.6M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Latvijas Juras medicinas has market cap of $5.6M and EV of $4.6M.
Latvijas Juras medicinas's trades at 0.4x EV/Revenue multiple, and 5.9x EV/EBITDA.
Equity research analysts estimate Latvijas Juras medicinas's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Latvijas Juras medicinas's P/E ratio is not available.
See valuation multiples for Latvijas Juras medicinas and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.6M | XXX | $5.6M | XXX | XXX | XXX |
| EV (current) | $4.6M | XXX | $4.6M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 0.4x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 5.9x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 62.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 28.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 21.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLatvijas Juras medicinas's revenue per employee in the last FY averaged $32K, while opex per employee averaged $1K for the same period.
Latvijas Juras medicinas's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Latvijas Juras medicinas's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Latvijas Juras medicinas and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 7% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $32K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Burjeel Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| PureHealth | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ramsay Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Athens Medical Centre | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Latvijas Juras medicinas acquired XXX companies to date.
Last acquisition by Latvijas Juras medicinas was XXXXXXXX, XXXXX XXXXX XXXXXX . Latvijas Juras medicinas acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Latvijas Juras medicinas founded? | Latvijas Juras medicinas was founded in 1996. |
| Where is Latvijas Juras medicinas headquartered? | Latvijas Juras medicinas is headquartered in Latvia. |
| How many employees does Latvijas Juras medicinas have? | As of today, Latvijas Juras medicinas has 359 employees. |
| Is Latvijas Juras medicinas publicy listed? | Yes, Latvijas Juras medicinas is a public company listed on RIS. |
| What is the stock symbol of Latvijas Juras medicinas? | Latvijas Juras medicinas trades under LJM1R ticker. |
| When did Latvijas Juras medicinas go public? | Latvijas Juras medicinas went public in 1998. |
| Who are competitors of Latvijas Juras medicinas? | Similar companies to Latvijas Juras medicinas include e.g. Burjeel Holdings, PureHealth, Integral Diagnostics, Ramsay Health. |
| What is the current market cap of Latvijas Juras medicinas? | Latvijas Juras medicinas's current market cap is $5.6M |
| Is Latvijas Juras medicinas profitable? | Yes, Latvijas Juras medicinas is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
